EN DE
Watch Medeon Biodesign for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medeon Biodesign (6499) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Medeon Biodesign stock TWD 50.44, price TWD 67.30, that is 25.1% below the price, quality 49 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006499007

MB Medeon Biodesign logo Thin data Nov 15, 2026

Medeon Biodesign

6499 · TWO

Expensive (fair value 25% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Quality 49/100 
Fair value 50.44 TWD · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −8.5 %/yr in TWD) 
Loss-making · -130.5% net margin (TTM) 
Negative free cash flow 
Trails peers (1/10) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Medeon Biodesign for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

145.00 TWD 35.05 TWD Fair Value 50.44 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range 35.05 TWD – 145.00 TWD · fair‑value band 37.83 TWD – 63.04 TWD · the 67.30 TWD price screens above the 50.44 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Medeon Biodesign in your weekly email

Every Wednesday you see whether Medeon Biodesign is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States.

Show moreShow less

The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure.

It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.

Stock analysis

Medeon Biodesign (6499) currently trades at 67.30 TWD, while our estimate is 50.44 TWD, 25% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 37.83 TWD (bear) to 63.04 TWD (bull), the price of 67.30 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Medeon Biodesign reported revenue of 419M TWD in FY2025 versus 69.0M TWD in FY2021, a compound +57.0%/yr. Reported net income was −668M TWD in FY2025.

Key figures

Market cap 6.5B TWD (≈ $198M) Micro · P/S ratio 16.5 · EPS (TTM) −5.96 TWD · Net margin −130% · Return on equity −51.2% · Return on assets (EBIT) −28.2% (5-year average) · Operating margin −132% · Revenue (TTM) 428M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 45% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −25%, 6499 screens cheaper than that median.

Fair Value

Bear 37.83 TWD Fair Value 50.44 TWD Bull 63.04 TWD
Price 67.30 TWD · Downside -25.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 78
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 96
Does it invest with discipline instead of growing at any price?
Low Volatility 55
How calm the share price moves, does not count
Price momentum 26
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 38
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+43.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.5%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.8% (2020) → −172.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6499 screens overvalued: fair value 25% below the price. Compare with Intuitive Surgical, Inc →

Compare Medeon Biodesign with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks

Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside −26.8% · Below median
Profitability
Return on assets −37.5% · Bottom 25%
Net margin (12 months) −130.5% · Bottom 25%
Operating margin (12 months) −131.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −3.4% · Bottom 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 4.53× · Priciest 25%
P/S (12 months) 15.60× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 21
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $88.65 $131.27 +48% vs 6499
EssilorLuxottica Société anonyme EL €184.50 €196.22 +6% vs 6499
Intuitive Surgical, Inc ISRG $437.75 $353.90 −19% vs 6499
Medline Inc MDLN $39.17 $28.59 −27% vs 6499
Alcon Inc ALC CHF 62.14 CHF 35.08 −44% vs 6499
Becton, Dickinson and Company BDX $216.47 $97.80 −55% vs 6499
Straumann Holding STMN CHF 108.75 CHF 45.50 −58% vs 6499
West Pharmaceutical Services, Inc WST $417.80 $139.22 −67% vs 6499
Sartorius Stedim Biotech S.A DIM €225.20 €54.82 −76% vs 6499
Sartorius Aktiengesellschaft SRT €226.50 €46.44 −80% vs 6499

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medeon Biodesign: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medeon Biodesign Fair Value". https://www.fairvalue-calculator.com/stock/6499

Frequently asked questions

Is Medeon Biodesign (6499) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is 50.44 TWD versus a price of 67.30 TWD, about 25% lower (overvalued).
What is the fair value of 6499?
Our estimate for Medeon Biodesign is 50.44 TWD (as of Nov 15, 2026), built from audited fundamentals. The current price: 67.30 TWD.
What is the quality score of 6499?
Medeon Biodesign has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medeon Biodesign (6499)?
Our calculated price target is the estimate of 50.44 TWD (as of Nov 15, 2026). Cautious scenario 37.83 TWD, optimistic scenario 63.04 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Medeon Biodesign stock forecast for 2026?
Our estimate puts fair value at 50.44 TWD, about 25% lower versus a price of 67.30 TWD (overvalued). Cautious scenario 37.83 TWD, optimistic scenario 63.04 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Medeon Biodesign (6499)?
Medeon Biodesign reported trailing-twelve-month revenue of about 428M TWD (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Medeon Biodesign (6499)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medeon Biodesign it is 50.44 TWD per share (as of Nov 15, 2026), against a price of 67.30 TWD.
Is Medeon Biodesign stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 6499 trades above its calculated fair value: price 67.30 TWD, fair value 50.44 TWD, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6499?
No. The price is what the market pays today (67.30 TWD); the fair value is what the company's own numbers justify (50.44 TWD). For Medeon Biodesign the two are 16.86 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Medeon Biodesign worth?
The market values Medeon Biodesign at about 6.5B TWD (market capitalisation, as of Nov 15, 2026). Per share that is 67.30 TWD; our models calculate a fair value of 50.44 TWD per share.
What do the bullish and bearish scenarios say about 6499?
Our models span a range for Medeon Biodesign: cautious scenario 37.83 TWD, base 50.44 TWD, optimistic 63.04 TWD per share (as of Nov 15, 2026, price 67.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medeon Biodesign (6499)?
Balance-sheet figures for Medeon Biodesign (as of Nov 15, 2026): return on equity −51.2%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 6499 from its 52-week high?
Medeon Biodesign trades at 67.30 TWD, about 45% below its 52-week high of 122.50 TWD and 21% above the low of 55.80 TWD (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 50.44 TWD is for.
Which stocks are comparable to Medeon Biodesign?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medeon Biodesign stock attractive at the current price?
The data as of Nov 15, 2026: price 67.30 TWD, calculated fair value 50.44 TWD (−25%), Quality Score 49/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Medeon Biodesign itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medeon Biodesign (6499)?
The closing price on Nov 17, 2026 was 67.30 TWD. Our estimate is 50.44 TWD, about 25% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medeon Biodesign right now?
The price sits above even our optimistic bull case (63.04 TWD). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Medeon Biodesign

How large is the market capitalisation of Medeon Biodesign (6499)?
The market capitalisation of Medeon Biodesign is 6.5B TWD (≈ $198M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medeon Biodesign (6499)?
The price-to-sales ratio of Medeon Biodesign is 16.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medeon Biodesign (6499)?
Earnings per share at Medeon Biodesign are −5.96 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medeon Biodesign (6499)?
The net margin of Medeon Biodesign is −130% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medeon Biodesign (6499)?
The return on equity (ROE) of Medeon Biodesign is −51.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medeon Biodesign (6499)?
On an EBIT basis the return on assets of Medeon Biodesign is −28.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medeon Biodesign (6499)?
The operating margin of Medeon Biodesign is −132% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medeon Biodesign (6499)?
Revenue at Medeon Biodesign is down 3.4% versus a year earlier (3y avg +12.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Medeon Biodesign (6499) generate?
The free cash flow of Medeon Biodesign is −646M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Medeon Biodesign in the live analysis

One click puts Medeon Biodesign on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.